SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2012
KYTHERA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
27200 West Agoura Road,
Calabasas, California 91301
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (818) 587-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
At a regularly scheduled meeting of the board of directors (the Board) of KYTHERA Biopharmaceuticals, Inc. (the Company) held on December 11, 2012, Hironori Hozoji informed the Company of his intention to resign from the Board effective December 14, 2012. Mr. Hozoji was originally elected to the Board in May 2008 in connection with an investment in the Company by JAFCO Co., Ltd., a venture capital firm in Tokyo, Japan (JAFCO). Mr. Hozojis resignation was at the request of JAFCO, where he currently serves as an Investment Officer at JAFCO Life Science Investments in San Diego, and was not a result of any disagreement with the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.